Zydus Lifesciences Limited, including its subsidiaries and affiliates (“Zydus”), has received a Notice of Compliance (NOC) from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths. This approval allows Zydus to enter the Canadian market with a cost-effective alternative for patients suffering from hypothyroidism, a condition caused by insufficient thyroid hormone production.
Liothyronine tablets contain a synthetic form of the thyroid hormone T3 (triiodothyronine), essential for regulating metabolism, energy levels, and overall thyroid function. The medication is a critical option for patients requiring precise thyroid hormone supplementation.
The ZDS-Liothyronine tablets will be manufactured at Zydus’ advanced facility in Ahmedabad SEZ, which meets international quality and safety standards. According to IQVIA MAT June 2025, Liothyronine tablets have recorded annual sales of 10.9 million CAD in Canada, highlighting the strong market potential for this therapy.
This approval marks another milestone in Zydus’ strategy to expand its global footprint in the generic pharmaceutical market while providing affordable, high-quality medicines.
